What is Leerink Partnrs’ Forecast for STOK Q1 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

STOK has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $8.15 on Friday. The company has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $5.93 and a 1 year high of $17.58. The stock’s fifty day moving average price is $9.47 and its 200-day moving average price is $11.45.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in the business. RTW Investments LP boosted its stake in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after acquiring an additional 471,240 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after acquiring an additional 265,395 shares during the period. Toronto Dominion Bank bought a new position in shares of Stoke Therapeutics in the fourth quarter worth about $35,001,000. State Street Corp boosted its stake in shares of Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after acquiring an additional 38,446 shares during the period.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock worth $143,332 over the last quarter. 11.30% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.